Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
Natural Alternatives International, Inc. reports developments in customized nutritional supplement manufacturing, proprietary ingredients, and customer supply relationships. The company formulates, manufactures, and markets nutritional supplements and provides strategic partnering services that include scientific research, product formulation, testing, packaging, regulatory review, and international product registration assistance.
Recurring announcements cover private-label contract manufacturing sales, quarterly results, manufacturing agreements, credit-facility updates, and the CarnoSyn® Brands portfolio. Product updates include CarnoSyn® beta-alanine, CarnoSyn® 4X, and TriBsyn® applications across sports performance, ready-to-drink beverages, protein drinks, dairy, and medical nutrition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Natural Alternatives International, Inc. (NAII) announced the publication of a new study in Nutrients demonstrating the cognitive benefits of SR CarnoSyn® beta-alanine tablets in older adults. Conducted with 100 participants aged 60-80, the double-blind study revealed significant improvements in cognitive function and reduced depression scores among those with baseline cognitive challenges. The study utilized a 600 mg tablet dosage, providing 2.4 grams daily. This research supports the extensive benefits of CarnoSyn® beta-alanine, already shown to enhance executive function and reduce mental fatigue, further solidifying NAII's commitment to science-backed nutritional supplements.
Natural Alternatives International (NAII) reported net income of $1.8 million, or $0.31 per diluted share, on $42.3 million in net sales for Q2 FY2023, an increase of 12.1% year-over-year. Private-label contract manufacturing sales surged 21.3% to $40.8 million. However, CarnoSyn® beta-alanine revenue fell 64%, reflecting a slowdown in the Sports Nutrition sector. For the first half of FY2023, net income decreased to $2.9 million from $5.1 million, with sales forecasts indicating a slight decline for the full fiscal year. The company is facing inflationary pressures and increased operational costs, negatively impacting profitability. Construction on a new plant in California is set to complete by spring 2023.
Natural Alternatives International, Inc. (NAII) has authorized a $1.0 million increase in its stock repurchase plan, raising the total to $19.0 million. This allows for continued buybacks based on market conditions. NAII has already repurchased 2.1 million shares and has $1.2 million remaining for future purchases. CEO Mark A. Le Doux expressed confidence in the company's value and growth, highlighting the upcoming operational launch of their new facility in Carlsbad, CA.